Eli Lilly considers BMS trademark opposition
Eli Lilly appears to be mulling whether to oppose a trademark registered by Bristol-Myers Squibb (BMS) at the US Patent and Trademark Office.
The mark, ‘ A chance to live longer’ (US number 87,319,390), was filed by BMS in January this year and published in July.
It covers international classes 5 (pharmaceutical preparations for the treatment of cancer); 16 (printed matter in the field of pharmaceutical preparations for the treatment of cancer); and 44 (medical information services providing information to physicians, healthcare professionals, and patients on the topic of cancer).
In August, Eli Lilly filed a request to extend the time to oppose the trademark. The request was granted by the Trademark Trial and Appeal Board (TTAB).
On Friday, November 17, Eli Lilly filed another request to extend the time to oppose.
The TTAB granted the extension until January 21, 2018.
BMS has used the slogan “A chance to live longer” in its adverts for Opdivo (nivolumab), an immunotherapy treatment.
Last week, LSIPR reported that Eli Lilly had been refused an injunction by the English High Court which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).
Cialis, a drug used to treat erectile dysfunction, had worldwide sales of nearly $2.3 billion in 2014.
Did you enjoy reading this story? Sign up to our free newsletters and get stories like this sent straight to your inbox.
